Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 26, 2018

UK researchers develop medical patch to treat mucosal conditions

Researchers at the University of Sheffield in the UK have partnered with Denmark-based firm Dermtreat to develop a new biodegradable plaster called Rivelin for the treatment of oral conditions.

Researchers at the University of Sheffield in the UK have partnered with Denmark-based firm Dermtreat to develop a new biodegradable plaster called Rivelin for the treatment of oral conditions.

The patch is made of special polymers that can stick to moist surfaces. It directly administers steroids to oral ulcers or lesions and forms a protective barrier around the affected area to speed-up its healing process.

“The plaster can be used to treat various mucosal conditions, including oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS), which lead to erosive and painful lesions in 1% to 2% of the population.”

Existing treatments for oral conditions comprise mouthwashes, creams and ointments that need to be used in the whole mouth, and are usually ineffective because of inadequate drug contact time with the lesion.

On the contrary, the new Rivelin patch is said to possess long adhesion time and high flexibility.

University of Sheffield School of Clinical Dentistry Oral Bioscience reader Craig Murdoch said: “The patch acts like a plaster inside your mouth, which means it is very effective at directly targeting the specific area as well as forming a protective barrier.

“Patients who have trialled the patch found it to be very comfortable to wear and they were really pleased with the length of adhesion which makes it particularly effective and efficient.”

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

The plaster can be used to treat various mucosal conditions, including oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS), which lead to erosive and painful lesions in 1% to 2% of the population.

Dermtreat plans to use its recent $17.7m funding to evaluate the Rivelin patch in Phase II clinical trials at multiple UK and US clinical sites.

The company is additionally sponsoring further studies to create the next generation of patches that will carry other useful drugs.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU